Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KDM6A | O15550 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.55 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.55 |
| ▸ | COMT | P21964 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331538 | 0.86 | KDM4E (0.57) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL2511740 | 0.85 | KDM4E (0.55) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL14311722 | 0.82 | KDM4E (0.57) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL8694192 | 0.80 | KDM4E (0.50) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL7151235 | 0.80 | KDM4E (0.50) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL15453041 | 0.80 | KDM4E (0.50) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL15457904 | 0.80 | KDM4E (0.50) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL9282434 | 0.80 | KDM4E (0.50) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL15453072 | 0.79 | KDM4E (0.49) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 | |
| SCHEMBL15457908 | 0.78 | KDM4E (0.52) | KDM4EKDM6AKDM4ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613560-B2 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | PRANA BIOTECHNOLOGY LTD (AU) | 2006-06-21 | — | — | EP | claimed |
| US-20040265847-A1 | Method for treating Alzheimer's disease | MASTERS COLIN LOUIS | 2004-12-30 | — | — | US | claimed |
| EP-0613560-B1 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | UNIV MELBOURNE (AU) | 1998-10-21 | — | — | EP | claimed |
| WO-1993010459-A1 | A METHOD FOR ASSAYING AND TREATING ALZHEIMER'S DISEASE | THE UNIVERSITY OF MELBOURNE (AU) | 1993-05-27 | — | — | WO | claimed |
| US-7629354-B2 | Removing amyloid deposits from brain without detrimental side effects; combining with such as clioquinol and vitamin B12; kits | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-12-08 | — | — | US | disclosed |
| US-20070275943-A1 | Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders | ACRUX DDS PTY LTD. | 2007-11-29 | — | — | US | disclosed |
| EP-1684761-A1 | METHOD AND COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF AMYLOIDOSIS DISORDERS | Acrux DDS Pty Ltd (AU) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005049026-A1 | METHOD AND COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF AMYLOIDOSIS DISORDERS | ACRUX DDS PTY LTD (AU) | 2005-06-02 | — | — | WO | disclosed |
| US-20050003018-A1 | Use of phanquinone for the treatment of Alzheimer's disease | P.N. GEROLYMATOS S.A. | 2005-01-06 | — | — | US | disclosed |
| US-6670369-B1 | To increase the solubility of amyloid-beta (A beta ) in the cerebrospinal fluid | P.N. GEROLYMATOS S.A. (GR) | 2003-12-30 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| EP-0959888-B1 | USE OF THE CHELATING AGENT CLIOQUINOL FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GEROLYMATOS P N SA (GR) | 2001-09-05 | — | — | EP | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| US-6001852-A | AND AN AMOUNT OF VITAMIN B.SUB.12 EFFECTIVE TO INHIBIT A DETRIMENTAL SIDE EFFECT | P.N. GEROLYMATOS S.A. (GR) | 1999-12-14 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050003018-A1 | Use of phanquinone for the treatment of Alzheimer's disease | PSEN2, PSEN1, RECQL | KDM4E 3525/4885KDM6A 2128/4885KDM4A 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.